Metabolic

AOD-9604

Controlled trials

A synthetic fragment of the C-terminus of human growth hormone.

SubQOralBeginnerNot approved anywherefat lossjoint and tendon health

Also known as hGH fragment 176-191 · AOD9604

At a glance

Dose summary

Typical dose300 mcg
Range250 mcg–500 mcg
FrequencyDaily
Half-lifeUnknown
ScheduleOnce daily
Cycle length12 weeks
RouteSubQ · Oral
Experience levelBeginner
Evidence gradeControlled trials
ApprovalNot approved anywhere
Where the dose comes fromCommunity practice, not a trial

No reliable human half-life has been published for AOD-9604, so none is listed rather than guessed at.

No regulator and no trial set these numbers. They describe what people actually do, recorded so you can see the range rather than guess at it — which is not the same thing as a recommendation.

Reconstitution

What to draw, at the usual vial

A 2 mg vial reconstituted with 2 mL of bacteriostatic water gives 1.00 mg/mL. A typical 300 mcg dose is 0.300 mL — pull the plunger to 30 units on a U-100 syringe.

Concentration1.00 mg/mL
Draw volume0.300 mL
U-100 units30 units
Doses per vial6

Same dose, other vial sizes

VialWaterConcentrationDrawUnitsDoses
2 mg2 mL1.00 mg/mL0.300 mL30 units6
5 mg2 mL2.50 mg/mL0.120 mL12 units16
6 mg2 mL3.00 mg/mL0.100 mL10 units20

The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.

Mechanism & evidence

What it is, and what is known

A synthetic fragment of the C-terminus of human growth hormone. It does not raise IGF-1 or act as a GH secretagogue. Human phase 2 obesity trials used oral doses up to 30 mg daily for 12 weeks and FAILED to beat placebo on weight loss, which is the strongest evidence available and it is negative. There is no dosing consensus for the subcutaneous route: the 250-500 mcg daily range here is a deliberately conservative, narrow band taken from common anecdotal protocols, not from a trial.

Treat any fat-loss or joint claim as unproven.

The caveat

The human phase 2 trial was negative — oral dosing failed to beat placebo on weight loss. That failure is the strongest human evidence this compound has.

Tolerability

Reported side effects

  • Injection site redness or itching
  • Headache
  • Generally well tolerated in trials, with an adverse event profile close to placebo

Hard stops

Do not use this if

  • Pregnancy, possible pregnancy, or breastfeeding
  • Under 18

These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.

Handling

Storage

Sealed powder, refrigerated24 months
After reconstitution, refrigerated28 days

Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.

Combinations

Commonly stacked with

Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.

References

Sources

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.